Therapeutic bacteriophage compositions

Abstract

The present invention relates to a bacteriophage composition comprising one or more (suitably two or more, or three) bacteriophages selected from Sa87, J-Sa36, or Sa83, or mutants thereof. Also encompassed are the use of said bacteriophage compositions for medical or non-medical applications, as well as kits, bandages, and wound dressings comprising said bacteriophage compositions.

1 . A bacteriophage composition comprising one or more bacteriophages selected from Sa87, J-Sa36, Sa83, and mutants thereof. 
     
     
         2 . A bacteriophage composition according to  claim 1  comprising at least two bacteriophages selected from Sa87, J-Sa36, Sa83, or mutants thereof. 
     
     
         3 . A bacteriophage composition according to  claim 1  or  2 , comprising bacteriophages Sa87, J-Sa36, Sa83, or mutants thereof. 
     
     
         4 . A bacteriophage composition according to any one of the preceding claims consisting essentially of Sa87, J-Sa36, and Sa83, or mutants thereof. 
     
     
         5 . A bacteriophage composition according to any one of the preceding claims, wherein the mutant has at least 75% sequence identity across its entire genome when compared to Sa87, J-Sa36, or Sa83. 
     
     
         6 . A bacteriophage composition according to any one of the preceding claims, wherein the mutant has at least 80% sequence identity across its entire genome when compared to Sa87, J-Sa36, or Sa83. 
     
     
         7 . A bacteriophage composition according to any one of the preceding claims, wherein the mutant has at least 90% sequence identity across its entire genome when compared to Sa87, J-Sa36, or Sa83. 
     
     
         8 . A bacteriophage composition according to any one of the preceding claims, wherein the mutant has at least 95% sequence identity across its entire genome when compared to Sa87, J-Sa36, or Sa83. 
     
     
         9 . A bacteriophage composition according to any one of the preceding claims further comprising an antibiotic (e.g. a chemical antibiotic). 
     
     
         10 . A bacteriophage composition according to any one of the preceding claims further comprising a pharmaceutically acceptable carrier, diluent, excipient or combinations thereof. 
     
     
         11 . A bacteriophage composition according to any one of the preceding claims for use as a medicament. 
     
     
         12 . A bacteriophage composition according to any one of the preceding claims for use in treating a bacterial infection. 
     
     
         13 . Use of a bacteriophage composition according to any one of the preceding claims in the manufacture of a medicament for treating a bacterial infection. 
     
     
         14 . A method of treating a bacterial infection comprising administering the bacteriophage composition according to any one of  claims 1 - 10  to a subject. 
     
     
         15 . A bacteriophage composition for use, use, or method according to any one of  claims 11 - 14 , wherein the bacterial infection is a  Staphylococcus aureus  bacterial infection. 
     
     
         16 . A bacteriophage composition for use, use, or method according to any one of  claims 11 - 15 , wherein the bacterial infection is a pulmonary bacterial infection. 
     
     
         17 . A bacteriophage composition for use, use, or method according to any one of  claims 11 - 16 , further comprising administering an antibiotic (e.g. a chemical antibiotic) to the subject. 
     
     
         18 . A kit comprising:
 a. a bacteriophage composition according to any one of  claims 1 - 10 ; and   b. instructions for use of same (e.g. in medicine).   
     
     
         19 . A kit according to  claim 18  further comprising an antibiotic (e.g. a chemical antibiotic) and instructions for use of same in combination with the bacteriophage composition. 
     
     
         20 . A kit according to  claim 18  or  19 , wherein said instructions are for use of same in treating a  Staphylococcus aureus  infection, preferably a  Staphylococcus aureus  pulmonary infection. 
     
     
         21 . A method of killing bacteria on a surface, said method comprising applying a bacteriophage composition according to any one of  claims 1 - 10  to the surface. 
     
     
         22 . A method according to  claim 21 , wherein the surface is the skin of a mammal, equipment (suitably medical equipment), bedding, furniture, walls, floors, or combinations thereof. 
     
     
         23 . Use of the bacteriophage composition according to any one of  claims 1 - 10  or the kit according to any one of  claims 18 - 20  for a non-medical application. 
     
     
         24 . A bandage or wound dressing comprising a bacteriophage composition according to any one of  claims 1 - 10 .